Key Points VK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phase 3 trials are successful. Tolerability and trial design adjustments are crucial for oral VK2735's success. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) is a much-loved stock on Wall Street. It's trading at around $30 a share at the time of this writing, but the analyst consensus target price on Visible Alpha is $90.89, with nine brokers rating it the equivalent of a buy and only one with a neutral rating on the stock.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。